These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 31867006)

  • 1. Harnessing NK Cells for Cancer Treatment.
    Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
    Front Immunol; 2019; 10():2836. PubMed ID: 31867006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
    Sun H; Sun C
    Front Immunol; 2019; 10():2354. PubMed ID: 31681269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells in cancer biology and therapy.
    Wu SY; Fu T; Jiang YZ; Shao ZM
    Mol Cancer; 2020 Aug; 19(1):120. PubMed ID: 32762681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.
    Pesce S; Greppi M; Grossi F; Del Zotto G; Moretta L; Sivori S; Genova C; Marcenaro E
    Front Immunol; 2019; 10():1242. PubMed ID: 31214193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.
    Kim N; Lee DH; Choi WS; Yi E; Kim H; Kim JM; Jin HS; Kim HS
    BMB Rep; 2021 Jan; 54(1):44-58. PubMed ID: 33298244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes.
    Pesce S; Trabanelli S; Di Vito C; Greppi M; Obino V; Guolo F; Minetto P; Bozzo M; Calvi M; Zaghi E; Candiani S; Lemoli RM; Jandus C; Mavilio D; Marcenaro E
    Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33255582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.
    Alfarra H; Weir J; Grieve S; Reiman T
    Front Immunol; 2020; 11():575609. PubMed ID: 33304346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Defects of Natural Killer Cells in Cancer Patients: Anarchy, Dysregulated Systemic Immunity, and Immunosuppression in Metastatic Cancer.
    Jewett A; Kos J; Kaur K; Turnsek TL; Breznik B; Senjor E; Wong P; Nguyen KY; Ko MW
    Crit Rev Immunol; 2020; 40(2):93-133. PubMed ID: 32749091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK Cell Dysfunction and Checkpoint Immunotherapy.
    Bi J; Tian Z
    Front Immunol; 2019; 10():1999. PubMed ID: 31552017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cells and ILCs in tumor immunotherapy.
    Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
    Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human NK cells: From surface receptors to clinical applications.
    Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
    Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting Human NK Cells in Tumor Therapy.
    Vacca P; Pietra G; Tumino N; Munari E; Mingari MC; Moretta L
    Front Immunol; 2019; 10():3013. PubMed ID: 32010130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy.
    Souza-Fonseca-Guimaraes F; Cursons J; Huntington ND
    Trends Immunol; 2019 Feb; 40(2):142-158. PubMed ID: 30639050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function.
    Li JH; O'Sullivan TE
    Front Immunol; 2021; 12():816658. PubMed ID: 35082797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.